Major ovarian cancer clinical study announced at Yale using combination drug therapy
28th Nov 2005, 14:39 GMT
A clinical study of ovarian cancer initiated by investigators at Yale School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women with recurrent ovarian cancer. .
Major ovarian cancer clinical study announced at Yale using combination drug therapy related news:
- Major ovarian cancer clinical study announced at Yale using combination drug therapy — KeralaNext: Science
- Major ovarian cancer clinical study announced at Yale using combination drug therapy, phenoxodiol with docetaxel — Medical News Today RSS/XML Feed
- New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale Univ School of Medicine — Operations-Related News from StratCenter.com
- New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale University School of Medicine — PR Newswire: All Releases
- AstraZeneca starts key study for new cancer drug — Reuters: Shares
- Distance from radiation therapy facility impacts breast cancer treatment — KeralaNext: Latest News
- Distance from radiation therapy facility impacts breast cancer treatment, USA — Medical News Today RSS/XML Feed
- Beer contains cancer fighting compound — The Cancer Blog
- $8.5 million to fund cancer drug development — Professional organisations latest news on Laboratorytalk
- NIH Attempts To Develop Ovarian Cancer Screening — NBC 17 - Health
Latest news from EurekAlert! - Medicine and Health:
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
- UCSD computer scientist wins Young Investigator Award, research on snake venom proteins highlighted
- Why do insects like to eat some plants more than others?
- Opposites do not attract
- Wild gorillas carriers of an SIV virus close to the AIDS virus
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
- Pourquié lab identifies genes involved in formation of vertebral precursors
- Artificial cornea offers better results for infants, some blind patients
- Healthier kids just the click of a remote away